Priming of naive T cells inside tumors leads to eradication of established tumors.

PubWeight™: 3.95‹?› | Rank: Top 1%

🔗 View Article (PMID 14704792)

Published in Nat Immunol on January 04, 2004

Authors

Ping Yu1, Youjin Lee, Wenhua Liu, Robert K Chin, Jing Wang, Yang Wang, Andrea Schietinger, Mary Philip, Hans Schreiber, Yang-Xin Fu

Author Affiliations

1: The Committee on Immunology and Department of Pathology, University of Chicago, MC3083, Chicago, IL 60637, USA.

Articles citing this

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95

Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21

Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21

Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res (2009) 3.83

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med (2006) 3.75

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell (2010) 3.52

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 3.11

Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev (2011) 3.05

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med (2005) 3.01

Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med (2010) 2.91

The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res (2011) 2.60

Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol (2004) 2.22

Ectopic lymphoid tissues and local immunity. Semin Immunol (2008) 2.18

Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med (2010) 1.97

The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest (2005) 1.82

T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res (2012) 1.74

A crucial role for HVEM and BTLA in preventing intestinal inflammation. J Exp Med (2008) 1.67

Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol (2007) 1.60

Retracted Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest (2004) 1.58

Shedding light on immunotherapy for cancer. N Engl J Med (2004) 1.54

Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways. Immunol Rev (2008) 1.49

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol (2008) 1.47

Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev (2009) 1.44

NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood (2005) 1.43

Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med (2010) 1.40

High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes. Oncoimmunology (2012) 1.28

The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunol Rev (2011) 1.27

Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci U S A (2007) 1.24

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest (2005) 1.24

Cancer immunotherapy. Mol Oncol (2012) 1.13

Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. Blood (2006) 1.12

The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol (2015) 1.06

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. Cancer Cell (2016) 1.03

In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res (2009) 1.00

Chemokines: can effector cells be redirected to the site of the tumor? Cancer J (2010) 0.98

Immunoregulation by tumor necrosis factor superfamily member LIGHT. Immunol Rev (2009) 0.98

Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine. Vaccine (2011) 0.98

In situ adenovirus vaccination engages T effector cells against cancer. Vaccine (2009) 0.97

Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol (2012) 0.96

Focal and segmental glomerulosclerosis induced in mice lacking decay-accelerating factor in T cells. J Clin Invest (2009) 0.96

Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners. Semin Immunopathol (2009) 0.96

Therapeutic use of dendritic cells to promote the extranodal priming of anti-tumor immunity. Front Immunol (2013) 0.92

Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases. J Transl Med (2013) 0.91

In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice. Cancer Res (2010) 0.91

Genetic evidence that intratumoral T-cell proliferation and activation are associated with recurrence and survival in patients with resected colorectal liver metastases. Cancer Immunol Res (2015) 0.89

Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat Commun (2015) 0.89

Immunotherapy and tumor microenvironment. Cancer Lett (2015) 0.88

Host immune response to infection and cancer: unexpected commonalities. Cell Host Microbe (2014) 0.88

Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine Growth Factor Rev (2008) 0.87

MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS). BMC Immunol (2013) 0.86

Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy. Cancer Gene Ther (2010) 0.86

Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity. Cancer Immunol Res (2013) 0.85

Licensed human natural killer cells aid dendritic cell maturation via TNFSF14/LIGHT. Proc Natl Acad Sci U S A (2014) 0.82

Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28 (CD28) and CD81. Proc Natl Acad Sci U S A (2012) 0.82

Inflammation-induced lymphangiogenesis and lymphatic dysfunction. Angiogenesis (2014) 0.81

Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model. PLoS One (2012) 0.81

Intratumoral administration of secondary lymphoid chemokine and unmethylated cytosine-phosphorothioate-guanine oligodeoxynucleotide synergistically inhibits tumor growth in vivo. J Korean Med Sci (2011) 0.81

Peripheral tissue homing receptor control of naïve, effector, and memory CD8 T cell localization in lymphoid and non-lymphoid tissues. Front Immunol (2013) 0.81

The role of costimulatory receptors of the tumour necrosis factor receptor family in atherosclerosis. J Biomed Biotechnol (2011) 0.81

Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer. Exp Ther Med (2011) 0.81

Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol (2015) 0.81

Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment. Adv Cancer Res (2015) 0.80

New immune therapy targets tumor-associated environment: from bone marrow to tumor site. Cell Mol Immunol (2011) 0.80

Targeting cytotoxic T lymphocytes for cancer immunotherapy. Br J Cancer (2004) 0.80

Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. MAbs (2012) 0.80

LIGHTing the way for tumor immunity. Nat Immunol (2004) 0.80

Progression of carcinogen-induced fibrosarcomas is associated with the accumulation of naïve CD4+ T cells via blood vessels and lymphatics. Int J Cancer (2013) 0.80

Dendritic Cells and Cancer Immunity. Trends Immunol (2016) 0.80

Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. Oncogene (2015) 0.79

Precise identification of immunotherapeutic targets for solid malignancies using clues within the tumor microenvironment-Evidence to turn on the LIGHT. Oncoimmunology (2015) 0.79

Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells. Cancer Gene Ther (2013) 0.79

Tumor-specific T cells signal tumor destruction via the lymphotoxin beta receptor. J Transl Med (2007) 0.79

Targeting and utilizing primary tumors as live vaccines: changing strategies. Cell Mol Immunol (2011) 0.79

LIGHT induces distinct signals to clear an AAV-expressed persistent antigen in the mouse liver and to induce liver inflammation. PLoS One (2010) 0.78

Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. Adv Cancer Res (2015) 0.78

Engineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse. Stem Cells Dev (2016) 0.78

LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours. Gut (2015) 0.77

Adenovirus-mediated LIGHT gene modification in murine B-cell lymphoma elicits a potent antitumor effect. Cell Mol Immunol (2010) 0.77

Identification of a major susceptibility locus for lethal graft-versus-host disease in MHC-matched mice. J Immunol (2009) 0.77

Understanding high endothelial venules: Lessons for cancer immunology. Oncoimmunology (2015) 0.76

Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes. Prostate (2014) 0.76

Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76

Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells. Biochem Soc Trans (2016) 0.76

Stromal Fibroblasts in Tertiary Lymphoid Structures: A Novel Target in Chronic Inflammation. Front Immunol (2016) 0.76

Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol (2016) 0.75

LIGHTing tumor up for checkpoint blockade. Oncotarget (2016) 0.75

Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory. Cancer Immunol Immunother (2011) 0.75

High Endothelial Venules and Other Blood Vessels: Critical Regulators of Lymphoid Organ Development and Function. Front Immunol (2017) 0.75

LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases. Cancer Res (2017) 0.75

Axl acts as a tumor suppressor by regulating LIGHT expression in T lymphoma. Oncotarget (2017) 0.75

Lentivirus-mediated LIGHT overexpression inhibits human colorectal carcinoma cell growth in vitro and in vivo. Oncol Lett (2013) 0.75

Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy. Cell Mol Immunol (2017) 0.75

Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines. Immunotherapy (2016) 0.75

De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat Immunol (2017) 0.75

Articles by these authors

A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78

Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science (2011) 13.16

WEGO: a web tool for plotting GO annotations. Nucleic Acids Res (2006) 13.06

Using FlyAtlas to identify better Drosophila melanogaster models of human disease. Nat Genet (2007) 12.62

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12

Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol (2008) 10.42

MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell (2007) 9.33

Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 9.17

Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol (2010) 9.01

Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med (2014) 8.73

The Genomes of Oryza sativa: a history of duplications. PLoS Biol (2005) 7.67

A draft sequence for the genome of the domesticated silkworm (Bombyx mori). Science (2004) 6.62

Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43

A genetic variation map for chicken with 2.8 million single-nucleotide polymorphisms. Nature (2004) 5.24

Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21

Self-monitoring in weight loss: a systematic review of the literature. J Am Diet Assoc (2011) 5.12

AlleleSeq: analysis of allele-specific expression and binding in a network framework. Mol Syst Biol (2011) 4.71

The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science (2009) 4.63

The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A (2012) 4.20

The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell (2012) 3.91

Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study. Biol Psychiatry (2005) 3.85

Glycolytic enzymes can modulate cellular life span. Cancer Res (2005) 3.78

Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab (2004) 3.75

Phosphatidylinositol 4 phosphate regulates targeting of clathrin adaptor AP-1 complexes to the Golgi. Cell (2003) 3.75

Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A (2008) 3.68

Large-gap quantum spin Hall insulators in tin films. Phys Rev Lett (2013) 3.60

Regulation of OsSPL14 by OsmiR156 defines ideal plant architecture in rice. Nat Genet (2010) 3.56

Genome dynamics and diversity of Shigella species, the etiologic agents of bacillary dysentery. Nucleic Acids Res (2005) 3.56

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell (2010) 3.52

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48

Adaptive immune cells temper initial innate responses. Nat Med (2007) 3.37

The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity (2011) 3.32

A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nat Med (2011) 3.17

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13

Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature (2010) 3.09

Dynamic regulatory network controlling TH17 cell differentiation. Nature (2013) 3.07

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06

HIV/STD risk behaviors and perceptions among rural-to-urban migrants in China. AIDS Educ Prev (2004) 3.04

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med (2005) 3.01

Evolution of the immunoglobulin heavy chain class switch recombination mechanism. Adv Immunol (2007) 2.94

Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci U S A (2010) 2.88

The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab (2008) 2.84

Recognition of host immune activation by Pseudomonas aeruginosa. Science (2005) 2.84

Variants in the fat mass- and obesity-associated (FTO) gene are not associated with obesity in a Chinese Han population. Diabetes (2007) 2.83

Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol (2005) 2.82

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79

Rapid cardiotonic effects of lipid emulsion infusion*. Crit Care Med (2013) 2.76

Stereotactic aspiration plus subsequent thrombolysis for moderate thalamic hemorrhage. World Neurosurg (2011) 2.75

BGI-RIS: an integrated information resource and comparative analysis workbench for rice genomics. Nucleic Acids Res (2004) 2.69

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68

Trends in physical activity, sedentary behavior, diet, and BMI among US adolescents, 2001-2009. Pediatrics (2013) 2.66

Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol (2004) 2.63

Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock. Science (2006) 2.62

The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res (2011) 2.60

A developmental approach to complex PTSD: childhood and adult cumulative trauma as predictors of symptom complexity. J Trauma Stress (2009) 2.59

Evolution, substrate specificity and subfamily classification of glycoside hydrolase family 5 (GH5). BMC Evol Biol (2012) 2.54

Bystander elimination of antigen loss variants in established tumors. Nat Med (2004) 2.53

PDGF signalling controls age-dependent proliferation in pancreatic β-cells. Nature (2011) 2.53

The effect of passengers and risk-taking friends on risky driving and crashes/near crashes among novice teenagers. J Adolesc Health (2011) 2.53

Involvement of the ubiquitin-proteasome system in the early stages of wallerian degeneration. Neuron (2003) 2.51

Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49

Physics. Learning and scientific reasoning. Science (2009) 2.49

PILRalpha is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B. Cell (2008) 2.49

A glimpse of streptococcal toxic shock syndrome from comparative genomics of S. suis 2 Chinese isolates. PLoS One (2007) 2.47

Lymphotoxin controls the IL-22 protection pathway in gut innate lymphoid cells during mucosal pathogen challenge. Cell Host Microbe (2011) 2.46

Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol (2006) 2.44

CD95 promotes tumour growth. Nature (2010) 2.42

Microarrays: retracing steps. Nat Med (2007) 2.39

A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med (2006) 2.36

Neointimal hyperplasia in early arteriovenous fistula failure. Am J Kidney Dis (2007) 2.34

Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J Virol (2003) 2.31

Local electronic properties of graphene on a BN substrate via scanning tunneling microscopy. Nano Lett (2011) 2.30

The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain (2007) 2.30

Crystal structure of the clathrin adaptor protein 1 core. Proc Natl Acad Sci U S A (2004) 2.28

BMP4 supports self-renewal of embryonic stem cells by inhibiting mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A (2004) 2.25

Crash and risky driving involvement among novice adolescent drivers and their parents. Am J Public Health (2011) 2.25

Serine proteases and their homologs in the Drosophila melanogaster genome: an initial analysis of sequence conservation and phylogenetic relationships. Gene (2003) 2.25

Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med (2002) 2.23

Historical variations in mutation rate in an epidemic pathogen, Yersinia pestis. Proc Natl Acad Sci U S A (2012) 2.22

Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. J Exp Med (2010) 2.22

The completion of the Mammalian Gene Collection (MGC). Genome Res (2009) 2.21

Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci (2010) 2.20

Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell (2013) 2.18

Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity (2002) 2.18

Prognostic value of coronary CT angiography and calcium score for major adverse cardiac events in outpatients. JACC Cardiovasc Imaging (2012) 2.17

Barriers to accessing TB diagnosis for rural-to-urban migrants with chronic cough in Chongqing, China: a mixed methods study. BMC Health Serv Res (2008) 2.17

Antidepressant effect on connectivity of the mood-regulating circuit: an FMRI study. Neuropsychopharmacology (2005) 2.16

Influenza Virus Database (IVDB): an integrated information resource and analysis platform for influenza virus research. Nucleic Acids Res (2006) 2.14